Detalhe da pesquisa
1.
Polatuzumab vedotin plus bendamustine and rituximab or obinutuzumab in relapsed/refractory follicular lymphoma: a phase Ib/II study.
Haematologica
; 109(4): 1194-1205, 2024 Apr 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37767550
2.
Polatuzumab vedotin, venetoclax, and an anti-CD20 monoclonal antibody in relapsed/refractory B-cell non-Hodgkin lymphoma.
Am J Hematol
; 2024 May 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-38700035
3.
Targeting MCL-1 and BCL-2 with polatuzumab vedotin and venetoclax overcomes treatment resistance in R/R non-Hodgkin lymphoma: Results from preclinical models and a Phase Ib study.
Am J Hematol
; 98(3): 449-463, 2023 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36594167
4.
Population pharmacokinetics of busulfan in pediatric and young adult patients undergoing hematopoietic cell transplant: a model-based dosing algorithm for personalized therapy and implementation into routine clinical use.
Ther Drug Monit
; 37(2): 236-45, 2015 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-25162216
5.
Polatuzumab vedotin plus rituximab and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma: a cohort of a multicentre, single-arm, phase 1b/2 study.
Lancet Haematol
; 11(2): e136-e146, 2024 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-38190832
6.
Busulfan, fludarabine, and alemtuzumab as a reduced toxicity regimen for children with malignant and nonmalignant diseases improves engraftment and graft-versus-host disease without delaying immune reconstitution.
Biol Blood Marrow Transplant
; 18(11): 1656-63, 2012 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-22609040
7.
Risk profiling of patients with relapsed/refractory diffuse large B-cell lymphoma by measuring circulating tumor DNA.
Blood Adv
; 6(6): 1651-1660, 2022 03 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-35086141
8.
Polatuzumab vedotin plus bendamustine and rituximab in relapsed/refractory DLBCL: survival update and new extension cohort data.
Blood Adv
; 6(2): 533-543, 2022 01 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-34749395
9.
Polatuzumab vedotin plus obinutuzumab and lenalidomide in patients with relapsed or refractory follicular lymphoma: a cohort of a multicentre, single-arm, phase 1b/2 study.
Lancet Haematol
; 8(12): e891-e901, 2021 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-34826412
10.
Safe and Effective Prophylaxis with Bimonthly Intravenous Pentamidine in the Pediatric Hematopoietic Stem Cell Transplant Population.
Pediatr Infect Dis J
; 35(2): 135-41, 2016 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-26418240